Norbert Kraut
@norbertkraut.bsky.social
Senior Executive Scientist, Discovery Research at Boehringer Ingelheim
Advancing science for healthier lives
Advancing science for healthier lives
Honored to share my journey from @embl.org PhD student to bringing new cancer drugs to patients, while working at
Boehringer Ingelheim.
Grateful and proud to be part of the amazing #EMBL family.
Boehringer Ingelheim.
Grateful and proud to be part of the amazing #EMBL family.
These days, Norbert Kraut often has exciting updates about cancer treatments.
An EMBL alumnus, he has spent the last decade focused on one of the hardest-to-treat lung cancers. 🧪
www.embl.org/news/people-...
An EMBL alumnus, he has spent the last decade focused on one of the hardest-to-treat lung cancers. 🧪
www.embl.org/news/people-...
EMBL alumni in action: Norbert Kraut | EMBL
Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.
www.embl.org
January 15, 2026 at 9:46 AM
Delighted to be featured in the latest issue of Xtalks Clinical Edge. With my colleague Vicky Brown, we cover advances and opportunities in treating non-small cell lung cancer (NSCLC) patients with precision oncology therapies. Big thanks to the XTalks team!
clinicaledge.xtalks.com/magazine/iss...
clinicaledge.xtalks.com/magazine/iss...
NSCLC Precision Oncology - Clinical Edge Issue 6
Precision oncology is reshaping how we understand and treat non-small cell lung cancer (NSCLC). Vicky Brown and Norbert Kraut of Boehringer Ingelheim discuss the science behind today’s targeted therap...
clinicaledge.xtalks.com
October 31, 2025 at 3:34 PM
Delighted to be featured in the latest issue of Xtalks Clinical Edge. With my colleague Vicky Brown, we cover advances and opportunities in treating non-small cell lung cancer (NSCLC) patients with precision oncology therapies. Big thanks to the XTalks team!
clinicaledge.xtalks.com/magazine/iss...
clinicaledge.xtalks.com/magazine/iss...
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer | Science Translational Medicine
Congrats @anirbanmaitra.bsky.social and @mdanderson.bsky.social @boehringerglobal.bsky.social teams
www.science.org/doi/10.1126/...
Congrats @anirbanmaitra.bsky.social and @mdanderson.bsky.social @boehringerglobal.bsky.social teams
www.science.org/doi/10.1126/...
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
The allele-agnostic mutant-KRAS inhibitor panKRASi inhibits the growth of murine and human pancreatic cancer and promotes antitumor immunity.
www.science.org
September 7, 2025 at 9:56 AM
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer | Science Translational Medicine
Congrats @anirbanmaitra.bsky.social and @mdanderson.bsky.social @boehringerglobal.bsky.social teams
www.science.org/doi/10.1126/...
Congrats @anirbanmaitra.bsky.social and @mdanderson.bsky.social @boehringerglobal.bsky.social teams
www.science.org/doi/10.1126/...
Reposted by Norbert Kraut
ICYMI last year in Cancer Discovery @aacrjournals.bsky.social: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers – by Birgit Wilding, Ralph Neumüller, et al. doi.org/10.1158/2159...
August 8, 2025 at 7:04 PM
ICYMI last year in Cancer Discovery @aacrjournals.bsky.social: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers – by Birgit Wilding, Ralph Neumüller, et al. doi.org/10.1158/2159...
Minisyposium on "Degraders and Glues" at #AACR25 co-chaired by Rima Al-awar and me this Tuesday, April 29, 2:30 pm CDT:
Hear about new degraders and molecular glues targeting #ALK, #CDK2, #KRAS, #TEAD, #AuroraA and #IKZF2
@theaacr.bsky.social
www.abstractsonline.com/pp8/#!/20273...
Hear about new degraders and molecular glues targeting #ALK, #CDK2, #KRAS, #TEAD, #AuroraA and #IKZF2
@theaacr.bsky.social
www.abstractsonline.com/pp8/#!/20273...
April 24, 2025 at 7:35 AM
Minisyposium on "Degraders and Glues" at #AACR25 co-chaired by Rima Al-awar and me this Tuesday, April 29, 2:30 pm CDT:
Hear about new degraders and molecular glues targeting #ALK, #CDK2, #KRAS, #TEAD, #AuroraA and #IKZF2
@theaacr.bsky.social
www.abstractsonline.com/pp8/#!/20273...
Hear about new degraders and molecular glues targeting #ALK, #CDK2, #KRAS, #TEAD, #AuroraA and #IKZF2
@theaacr.bsky.social
www.abstractsonline.com/pp8/#!/20273...
Tackling Cancer through Global Team Science #cancergrandchallenges @theaacr.bsky.social aacrjournals.org/cancerdiscov...
Tackling Cancer through Global Team Science
Summary:. Here, we discuss the seven new challenges set by Cancer Grand Challenges that are currently open for creative applications. We invite the research community to assemble global, interdiscipli...
aacrjournals.org
March 9, 2025 at 2:23 PM
Tackling Cancer through Global Team Science #cancergrandchallenges @theaacr.bsky.social aacrjournals.org/cancerdiscov...
Excited to see our paper in print in Cancer Discovery @theaacr.bsky.social
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent inhi...
aacrjournals.org
January 13, 2025 at 5:33 PM
Excited to see our paper in print in Cancer Discovery @theaacr.bsky.social
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
KRAS inhibitors: resistance drivers and combinatorial strategies: Trends in Cancer cell.com/trends/cance...
December 31, 2024 at 9:05 AM
KRAS inhibitors: resistance drivers and combinatorial strategies: Trends in Cancer cell.com/trends/cance...
Hot off the press: Our work with #KRASmulti inhibitors suggests novel therapeutic concept for #cancers harboring #KRAS amplifications. Just published by our team at Boehringer Ingelheim in @theaacr.bsky.social journal Molecular Cancer Therapeutics.
aacrjournals.org/mct/article/...
aacrjournals.org/mct/article/...
December 24, 2024 at 5:02 AM
Hot off the press: Our work with #KRASmulti inhibitors suggests novel therapeutic concept for #cancers harboring #KRAS amplifications. Just published by our team at Boehringer Ingelheim in @theaacr.bsky.social journal Molecular Cancer Therapeutics.
aacrjournals.org/mct/article/...
aacrjournals.org/mct/article/...
Out now:
Preclinical studies on a new bispecific antibody from the ongoing Boehringer Ingelheim @mdanderson.bsky.social
collaboration:
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive #PancreaticCancer
www.tandfonline.com/doi/10.1080/...
Preclinical studies on a new bispecific antibody from the ongoing Boehringer Ingelheim @mdanderson.bsky.social
collaboration:
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive #PancreaticCancer
www.tandfonline.com/doi/10.1080/...
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
Exploitation of extrinsic apoptosis signaling via TRAILR2 activation represents a promising therapeutic concept in cancer treatment. The limited clinical success of previous TRAILR2 agonistic agent...
www.tandfonline.com
December 11, 2024 at 5:25 AM
Out now:
Preclinical studies on a new bispecific antibody from the ongoing Boehringer Ingelheim @mdanderson.bsky.social
collaboration:
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive #PancreaticCancer
www.tandfonline.com/doi/10.1080/...
Preclinical studies on a new bispecific antibody from the ongoing Boehringer Ingelheim @mdanderson.bsky.social
collaboration:
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive #PancreaticCancer
www.tandfonline.com/doi/10.1080/...
Great story @obenaufa.bsky.social and team. Congrats to a wonderful paper in @natureportfolio.bsky.social
1/23 Big news for the #ObenaufLab! So excited to finally share our new study providing another puzzle piece, why immunotherapy fails in many tumors, now out in @Nature 🧵👇 www.nature.com/articles/s41...
November 27, 2024 at 6:22 PM
Great story @obenaufa.bsky.social and team. Congrats to a wonderful paper in @natureportfolio.bsky.social